Previous studies reported poor outcome, likely due to the inclusion of isocitrate dehydrogenase (IDH) wildtype astrocytomas and advocated defensive surgical and adjuvant treatment. Here, IDH3A is linked to astrocytoma (excluding glioblastoma).